Latest Distribution Partnerships News

Zimi Limited has paused its planned capital raising amid ongoing talks, while revealing strong operational momentum including $1.42 million in open orders and expanded market partnerships.

4DMedical has landed a significant commercial contract with Intermountain Health to deploy its FDA-cleared Pulmonary Hypertension Analysis (PHA™) product, marking a key milestone in its U.S. expansion through a strategic Microsoft-backed partnership.

Zimi Limited confirms $1.42 million in open orders with key distributor GSM Electrical, backed by shareholder approval for up to $6 million in future sales. The company also advances its commercial market ambitions through a new partnership with Zencontrol.

Volt Group Limited reported a robust 26.8% revenue increase in Q1 FY25, driven by strong performances in its EcoQuip and Wescone divisions, alongside promising advances in its ATEN Waste Heat to Power technology.

Elixinol Wellness reported a 13.7% year-on-year revenue increase in Q1 FY25, despite a softer quarter compared to record Q4, with ecommerce momentum and strategic initiatives setting the stage for margin recovery and growth in H2.

Tissue Repair Limited reports progress in its Phase 3 clinical trials for TR987® despite enrollment delays caused by US regulatory disruptions, while TR Pro+® sales hit record highs and manufacturing scale-up advances.

Orthocell has secured Health Canada approval for its nerve repair product Remplir™, adding the US$75 million Canadian market and expanding its total addressable market to US$1.8 billion. The company plans to appoint local distributors and expects first sales in H2 2025.

BauMart Holdings has unveiled a multi-pronged strategy to tackle construction labour shortages, advance green building materials, and expand mining equipment services, supported by a $482,000 rights issue.

Telix Pharmaceuticals has gained UK MHRA approval for Illuccix, its advanced prostate cancer PET imaging agent, promising to alleviate supply shortages and improve diagnostic accuracy across the UK.

Yowie Group’s Q2 FY25 results reveal a mixed performance with a 33% revenue drop in North America offset by growth in Australia and ongoing cost optimisation efforts.

Tissue Repair Limited reports initial patient enrolment in its pivotal Phase 3 trial for TR987®, alongside a robust 35% quarterly sales increase for its TR Pro+® product. The company is also advancing manufacturing and distribution strategies to support growth.

Vectus Biosystems reports completion of Phase Ib trials for its lead drug VB0004 and a robust cash position bolstered by a significant R&D tax refund, setting the stage for licensing discussions.